Tevogen Bio Holdings Inc. (TVGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tevogen Bio Holdings Inc. on March 25, 2026, covering events occurring on March 20, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Warren, New Jersey. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols TVGN and TVGNW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
The primary material event reported is the Company's regained compliance with the Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement. This status was achieved following a 1-for-50 reverse stock split that became effective on March 6, 2026. Consequently, the matter regarding the Company's listing compliance is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the listing deficiency. The document confirms the successful implementation of the reverse split as a corrective measure for the minimum bid price requirement.
Investor Verification Checklist
- Verify the effective date and ratio of the 1-for-50 reverse stock split (effective March 6, 2026).
- Confirm the current trading status of TVGN and TVGNW on The Nasdaq Global Market.
- Review the Company's prior Form 8-K filed on March 4, 2026, for detailed information regarding the reverse split mechanics.
- Monitor future filings for any new compliance notices or financial updates, as this report contains no financial data.